{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nalidixic acid
to a specific field?
Status:
Investigational
Source:
INN:peliglitazar [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Peliglitazar (also known as BMS 426707-01), a dual α/γ peroxisome proliferator-activated receptor agonist, has been studied in phase I/II clinical trial in patients with type 2 diabetes mellitus. However, this study was discontinued.
Status:
Investigational
Source:
NCT04575038: Phase 2 Interventional Completed COVID-19 Infection
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Brequinar is a synthetic quinolinecarboxylic acid analogue with antineoplastic properties. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. Brequinar had been in phase II clinical trials by Bristol-Myers Squibb for the treatment of cancer and transplant rejection. However, this research has been discontinued.
Brequinar had been also in preclinical studys for the treatment of cytomegalovirus infections. However, this research has been discontinued.
Status:
Investigational
Source:
NCT00808977: Phase 2 Interventional Completed Ulcerative Colitis
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Dersalazine is a locally-acting compound. It is a potent platelet activating factor (PAF)-antagonist. Dersalazine inhibited IL-1beta or TNF-alpha production in THP-1 or U937 cells, respectively. Dersalazine sodium reduced colonic proinflammatory cytokines IL-1b, IL-6, and IL-17 in dextran sodium sulphate (DSS)–induced colitis. After oral administration, dersalazine sodium is mostly unabsorbed until it reaches the large bowel where the azo bond is reduced by bacteria releasing the active compound. Dersalazine had been in phase I clinical trial for the treatment of ulcerative colitis. No serious adverse reactions were detected in clinical trial. However, no recent development has been reported.
Class (Stereo):
CHEMICAL (ACHIRAL)
Brocrinat is an ethacrynic acid derivative with diuretic activity. Chronic dosing with Brocrinat does not increase plasma uric acid suggests that therapeutically, Brocrinat as a diuretic may be useful in patients where control of plasma uric acid is desirable..
Status:
Investigational
Source:
INN:ertiprotafib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Ertiprotafib was originally developed as an inhibitor of PTP1B. Multiple targets of ertiprotafib, in addition to PTP1B inhibition, have been suggested including dual PPARalpha/PPARgamma agonism and IKK-beta inhibition. It normalized the plasma glucose and insulin levels in diabetic animal models and progressed to a phase II clinical trial for the treatment of Type 2 diabetes mellitus. Ertiprotafib development has been discontinued.
Status:
Investigational
Source:
INN:cyclobutoic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Cyclobutoic acid is a synthetic analog of mevalonic acid, developed by the Italian company Farmitalia Carlo Erba SPA. The compound inhibited the incorporation of [14C] into CO2, fatty acids and cholesterol, and was used for the treatment of hepatic deficiency.
Status:
Investigational
Source:
NCT00295724: Phase 3 Interventional Completed Chronic Low Back Pain
(2005)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Bicifadine (DOV-220075) is not a narcotic and is well-tolerated and, in preclinical studies, has been shown not to act at any opiate receptor, but inhibits monoamine neurotransmitter uptake by recombinant human transporters in vitro with a relative potency of norepinephrine:serotonin:dopamine of 1:2:17. Bicifadine was in Phase II clinical trial for pain caused by diabetic neuropathy, in addition, was in phase III clinical trial to treat Chronic Low Back Pain, but that studies were discontinued
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Sulfaloxic acid is a benzamide derivative patented by Chemische Fabrik von Heyden A.-G. as an antibacterial agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Etoxeridine (Carbetidine or Wy2039), a piperidine derivative, is a narcotic analgetic.
Status:
Investigational
Source:
NCT03329885: Phase 1/Phase 2 Interventional Terminated Rheumatoid Arthritis
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
